A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
Status:
Recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, two arms, randomized, phase I study evaluating the safety
and tolerability as well as some activity parameters of TG4050 in patients with squamous cell
carcinoma of the head and neck (SCCHN).